Cresco Labs (FRA:6CQ) Cyclically Adjusted Revenue per Share: € (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6CQ Cresco Labs Inc FRA:6CQ
63 GF Score
Price €0.62
GF Value €0.73
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cresco Labs Cyclically Adjusted Revenue per Share?

Cresco Labs FRA:6CQ +0.97% 63 Cyclically Adjusted Revenue per Share is € as of Jun. 2026. GuruFocus rates FRA:6CQ with a GF Score™ of 63/100 and a GF Value™ of €0.73 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cresco Labs's adjusted revenue per share for the three months ended in Jun. 2026 was €0.316. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Cresco Labs's average Cyclically Adjusted Revenue Growth Rate was -0.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cresco Labs was 30.30% per year. The lowest was 0.90% per year. And the median was 11.30% per year.

As of today (2026-09-20), Cresco Labs's current stock price is €0.623. Cresco Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was . Cresco Labs's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cresco Labs was 17.75. The lowest was 0.18. And the median was 1.06.


Cresco Labs  (FRA:6CQ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cresco Labs was 17.75. The lowest was 0.18. And the median was 1.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cresco Labs Cyclically Adjusted Revenue per Share Related Terms


Cresco Labs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cresco Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cresco Labs Cyclically Adjusted Revenue per Share Chart

Cresco Labs Annual Data
Trend Jan16 Jan17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cresco Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:6CQ vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cresco Labs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cresco Labs's Cyclically Adjusted PS Ratio falls into.


FRA:6CQ
63GF Score
Cresco Labs Inc FRA:6CQ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cresco Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cresco Labs's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.316/333.9520*333.9520
=0.316

Current CPI (Jun. 2026) = 333.9520.

Cresco Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201510 0.000 237.838 0.000
201601 0.000 236.916 0.000
201604 0.000 239.261 0.000
201607 0.000 240.628 0.000
201610 0.000 241.729 0.000
201701 0.000 242.839 0.000
201704 0.000 244.524 0.000
201707 0.000 244.786 0.000
201710 0.000 246.663 0.000
201812 0.135 251.233 0.179
201903 0.164 254.202 0.215
201906 0.235 256.143 0.306
201909 0.282 256.759 0.367
201912 0.283 256.974 0.368
202003 0.305 258.115 0.395
202006 0.415 257.797 0.538
202009 0.360 260.280 0.462
202012 0.608 260.474 0.780
202103 0.623 264.877 0.785
202106 0.670 271.696 0.824
202109 0.674 274.310 0.821
202112 0.662 278.802 0.793
202203 0.653 287.504 0.758
202206 0.691 296.311 0.779
202209 0.694 296.808 0.781
202212 0.649 296.797 0.730
202303 0.594 301.836 0.657
202306 0.580 305.109 0.635
202309 0.519 307.789 0.563
202312 0.515 306.746 0.561
202403 0.497 312.332 0.531
202406 0.496 314.175 0.527
202409 0.471 315.301 0.499
202412 0.472 315.605 0.499
202503 0.450 319.799 0.470
202506 0.407 322.561 0.421
202509 0.397 324.800 0.408
202512 0.386 324.054 0.398
202603 0.355 330.213 0.359
202606 0.316 333.952 0.316

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of € mean?
Cresco Labs (FRA:6CQ) has a Cyclically Adjusted Revenue per Share of € as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cresco Labs and its competitors.
Is Cresco Labs' Cyclically Adjusted Revenue per Share too high?
Cresco Labs' current Cyclically Adjusted Revenue per Share is €. Overall, Cresco Labs has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' Cyclically Adjusted Revenue per Share compare to ZTS?
Cresco Labs' Cyclically Adjusted Revenue per Share of € can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cresco Labs and its competitors. Cresco Labs's current Cyclically Adjusted Revenue per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.73, compared to a current price of €0.62 — trading 14.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €. Cresco Labs' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current Cyclically Adjusted Revenue per Share is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cresco Labs (FRA:6CQ) Overvalued in 2026?

Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued. The current stock price of €0.62 is trading 14.7% below its estimated GF Value™ of €0.73. GuruFocus considers Cresco Labs to be Modestly Undervalued.

Key valuation signals for FRA:6CQ:

  • Cyclically Adjusted Revenue per Share:
  • GF Value™: €0.73 vs. price of €0.62 (14.7% below fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cresco Labs Business Description

Address 600 W. Fulton Street, Suite 800, Chicago, IL, USA, 60661
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
63GF Score

Get the complete analysis for FRA:6CQ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.62
Price
€0.73
GF Value